Blog
RSS FeedPosted by Michael Wonder on 10 Apr 2023
Cheaper medicines for graft versus host disease, chronic rhinosinusitis and oesophageal cancer
10 April 2023 - For the first time Jakavi (ruxolitinib) will be listed for the treatment of patients with either acute ...
Posted by Michael Wonder on 06 Apr 2023
Public summary documents – December 2022 PBAC meeting
6 April 2023 - The public summary documents (positive recommendations and subsequent decisions not to recommend) from the December 2022 PBAC ...
Posted by Michael Wonder on 06 Apr 2023
Life changing cystic fibrosis treatment now available to children 6 years and above
6 April 2023 - From 1 May 2023, children aged 6 to 11 with cystic fibrosis will have access to ...
Posted by Michael Wonder on 05 Apr 2023
‘An absolute game changer’: children under 12 to receive life saving drug
6 April 2023 - Hundreds of children with cystic fibrosis will have subsidised access to the life-changing medication Trikafta from ...
Posted by Michael Wonder on 03 Apr 2023
Nucala (mepolizumab) is now listed on the PBS for Australians with chronic rhinosinusitis with nasal polyps
3 April 2023 - Nucala is the first biologic treatment to be PBS-subsidised for the treatment of severe chronic rhinosinusitis with ...
Posted by Michael Wonder on 01 Apr 2023
Schedule of Pharmaceutical Benefits - 1 April 2023
1 April 2023 - The April 2023 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 01 Apr 2023
Outcome statement - February 2023 DUSC meeting
31 March 2023 - The outcome statement from the February 2023 DUSC meeting is now available. ...
Posted by Michael Wonder on 30 Mar 2023
Expanded access to subsidised oral antiviral Paxlovid and other COVID-19 supports
30 March 2023 - From 1 April, more than 160,000 people aged 60 to 69 will have access to the ...
Posted by Michael Wonder on 29 Mar 2023
Agenda for the July 2023 PBAC meeting
29 March 2023 - The agenda for the July 2023 PBAC meeting is now available. ...
Posted by Michael Wonder on 22 Mar 2023
HTA reform gets underway – terms of reference released today
22 March 2023 - Medicines Australia acknowledges the Health Technology Assessment Review Terms of Reference – released today – and ...
Posted by Michael Wonder on 22 Mar 2023
Terms of reference for the Health Technology Assessment Policy and Methods Review
22 March 2023 - The terms of reference for the Health Technology Assessment Policy and Methods Review is now available. ...
Posted by Michael Wonder on 19 Mar 2023
Public Summary Documents (first time decisions not to recommend and deferrals) - November 2022 PBAC meeting
17 March 2023 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the November 2022 PBAC ...
Posted by Michael Wonder on 17 Mar 2023
Government maintains access to fast acting insulin
17 March 2023 - The Albanese Government has secured access to Fiasp and Fiasp FlexTouch on the PBS for Australians ...
Posted by Michael Wonder on 14 Mar 2023
CEO’s appointment to HTA Review Reference Committee
15 March 2023 - CEO of Medicines Australia, Elizabeth de Somer, has been appointed as the medicines industry representative on ...
Posted by Michael Wonder on 09 Mar 2023
Updates from the Health Technology Assessment Policy and Methods Review Reference Committee (March 2023)
9 March 2023 - The Health Technology Assessment Policy and Methods Review Reference Committee met on 13 February 2023. ...